Double-blind, randomized, controlled trial of Rasagiline as monotherapy in early Parkinson's Disease patients
Identifieur interne : 005A08 ( Main/Merge ); précédent : 005A07; suivant : 005A09Double-blind, randomized, controlled trial of Rasagiline as monotherapy in early Parkinson's Disease patients
Auteurs : Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2004.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel-group, double-blind, randomized, placebo-controlled, 10-week study. Fifty-six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3-week dose-escalation period was followed by a 7-week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were -1.8 (±1.3), -3.6 (±1.7), -3.6 (±1.2), and -0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002099
- to stream PascalFrancis, to step Curation: 000C22
- to stream PascalFrancis, to step Checkpoint: 002170
Links to Exploration step
Pascal:04-0494461Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Double-blind, randomized, controlled trial of Rasagiline as monotherapy in early Parkinson's Disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Yale University School of Medicine</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine</s1>
<s2>Detroit</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Detroit</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Clinical Neuroscience Center</s1>
<s2>Southfield, Michigan</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Beth Israel Deaconess Medical Center</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0494461</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0494461 INIST</idno>
<idno type="RBID">Pascal:04-0494461</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002099</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000C22</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002170</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Stern M:double:blind:randomized</idno>
<idno type="wicri:Area/Main/Merge">005A08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Double-blind, randomized, controlled trial of Rasagiline as monotherapy in early Parkinson's Disease patients</title>
<author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Yale University School of Medicine</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departments of Neurology, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine</s1>
<s2>Detroit</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Detroit</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Clinical Neuroscience Center</s1>
<s2>Southfield, Michigan</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Beth Israel Deaconess Medical Center</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Rasagiline</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Rasagiline</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rasagiline (N-propargyl-1(R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel-group, double-blind, randomized, placebo-controlled, 10-week study. Fifty-six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3-week dose-escalation period was followed by a 7-week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were -1.8 (±1.3), -3.6 (±1.7), -3.6 (±1.2), and -0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo (P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Connecticut</li>
<li>Floride</li>
<li>Massachusetts</li>
<li>Michigan</li>
<li>Pennsylvanie</li>
<li>Rhode Island</li>
<li>État de New York</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name>
</region>
<name sortKey="Friedman, Joseph" sort="Friedman, Joseph" uniqKey="Friedman J" first="Joseph" last="Friedman">Joseph Friedman</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name>
<name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005A08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005A08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:04-0494461 |texte= Double-blind, randomized, controlled trial of Rasagiline as monotherapy in early Parkinson's Disease patients }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |